Andere talen Lyra Therapeutics, Inc.

Aandelen

LYRA

US55234L1052

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
5,19 ^USD	-3,71%		-1,70%	-0,95%

22/03	Lyra Therapeutics dient $300 miljoen in voor een gemengd aanbod op de beurs	MT
21/03	Lyra Therapeutics, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Lyra Therapeutics Files $300 Million Mixed Shelf Offering	22/03
Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	21/03
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	01/03
Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	07/11
Lyra Therapeutics to Participate in Upcoming Investor Conferences	07/11
Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer	16-10-23
Lyra Therapeutics, Inc Announces Appointment of Ronan O?Brien as Chief Legal Officer	16-10-23
Lyra Therapeutics Says Phase 2 Trial for Chronic Rhinosinusitis Treatment Meets Primary Endpoint	12-09-23
Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery	12-09-23
Lyra Therapeutics Announces Positive Topline Results from Beacon Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis in Patients with Prior Ethmoid Sinus Surgery	12-09-23
Lyra Therapeutics to Participate in Upcoming Investor Conferences	06-09-23
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis	29-08-23
North American Morning Briefing : China Angst -2-	15-08-23
Lyra Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08-08-23
Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update	08-08-23
Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference	13-07-23
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell Microcap Value Index	23-06-23
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell 3000E Value Index	23-06-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Lyra Therapeutics, Inc.

Aandelen

LYRA

US55234L1052

Andere talen

Filters